Document:

exv10w1

 

Exhibit 10.1

FIRST AMENDMENT TO

AMENDED AND RESTATED

SPECIAL EQUITY AGREEMENT

     This First Amendment to the Amended and Restated Special Equity Agreement dated as of March 5,
2003 (the “Agreement”) by and between ProLogis and K. Dane Brooksher (“Brooksher”, referred to in
the Agreement as the “CEO”), is entered into as of September 22, 2005 (the “Effective Date”);

WITNESSETH THAT:

     WHEREAS, ProLogis and Brooksher are parties to the Agreement; and

     WHEREAS, the parties desire to amend certain provisions of the Agreement as herein provided.

     NOW, THEREFORE, in consideration of the premises and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereby amend the
Agreement as follows:

     1. Section 4(b)(i) of the Agreement is hereby deleted in its entirety and replaced with the
following:

(i) serve on the board of directors or trustees of or serve as an officer or
employee of any industrial real estate investment trust with a class of securities
registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as
amended, or

[Remainder of Page Intentionally Left Blank]

 

 

     IN WITNESS WHEREOF, Brooksher has hereunto set his hand and ProLogis has caused these presents
to be executed in its name and on its behalf, all as of the day and year first above written.

	 	 	 	 	 
	 	 	 
	 	     /s/ K. Dane Brooksher
 	 
	 	K. Dane Brooksher 	 
	 	 	 
	 

	 	 	 	 	 
	 	ProLogis

 	 
	 
	 
	Acknowledged and Agreed: 	By:  	/s/ Edward S. Nekritz
 	 
	 	 	Edward S. Nekritz 	 
	 	 	Secretary and General Counsel 	 

				
	 	 
	By:  	/s/ Donald P. Jacobs 	 
	 	Donald P. Jacobs 	 
	 	Chairman

Management Development & Compensation

Committeeexv10w2

 

Exhibit 10.2

FIRST AMENDMENT TO

SPECIAL EQUITY AGREEMENT

     This First Amendment to the Special Equity Agreement dated as of March 5, 2003 (the
“Agreement”) by and between ProLogis and Irving F. Lyons, III (“Lyons”, referred to in the
Agreement as the “Executive”), is entered into as of September 22, 2005, (the “Effective Date”);

WITNESSETH THAT:

     WHEREAS, ProLogis and Lyons are parties to the Agreement; and

     WHEREAS, the parties desire to amend certain provisions of the Agreement as herein provided.

     NOW, THEREFORE, in consideration of the premises and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereby amend the
Agreement as follows:

     1. Section 3(b)(i) of the Agreement is hereby deleted in its entirety and replaced with the
following:

(i) serve on the board of directors or trustees of or serve as an officer or
employee of any industrial real estate investment trust with a class of securities
registered under Section 12(b) or 12(g) of the Securities Exchange Act of 1934, as
amended, or

[Remainder of Page Intentionally Left Blank]

 

 

     IN WITNESS WHEREOF, Lyons has hereunto set his hand and ProLogis has caused these presents to
be executed in its name and on its behalf, all as of the day and year first above written.

	 	 	 	 	 
	 	 	 
	 	                                      /s/ Irving F. Lyons, III
 	 
	 	Irving F. Lyons, III 	 
	 	 	 
	 

	 	 	 	 	 
	 	ProLogis

 	 
	 
	 
	Acknowledged and Agreed: 	By:  	/s/ Edward S. Nekritz
 	 
	 	 	Edward S. Nekritz 	 
	 	 	Secretary and General Counsel 	 

				
	 	 
	By:  	/s/ Donald P. Jacobs
 	 
	 	Donald P. Jacobs 	 
	 	Chairman

Management Development & Compensation

CommitteeEXHIBIT 10.1

                 DEVELOPMENT, DISTRIBUTION AND SUPPLY AGREEMENT

         THIS AGREEMENT ("Agreement") is made this 22nd day of September, 2005,
by and between Specialized Health Products International, Inc., having an
address at 585 West 500 South, Bountiful, Utah 84010 (hereinafter referred to as
"SHPI"), and Bard Access Systems, Inc., a Utah corporation having a place of
business at 5425 West Amelia Earhart Drive, Salt Lake City, Utah 84116
(hereinafter referred to as "BAS").

                                    RECITALS

         WHEREAS, SHPI owns intellectual property related to safety infusion
sets,
         WHEREAS, BAS desires to fund SHPI's efforts to develop a power
injectable safety winged infusion set that meets BAS's requirements,
         WHEREAS, BAS further desires to obtain the right to distribute such
power injectable safety winged infusion set worldwide for use in the Field (as
such term is hereinafter defined),
         WHEREAS, SHPI is willing to grant such distribution rights to BAS, all
on the terms and conditions hereinafter set forth,
         WHEREAS, BAS also desires to have SHPI manufacture, package and supply
BAS with the aforementioned power injectable safety winged infusion set,
         WHEREAS, SHPI desires to manufacture, package and supply BAS with the
aforementioned power injectable safety winged infusion set, and
         WHEREAS, the parties are willing to carry out the foregoing pursuant to
the terms and conditions set forth in this Agreement;
         NOW, THEREFORE, in consideration of the terms and conditions set forth
in this Agreement and for other good and valuable consideration, the receipt and
sufficiency of which is acknowledged by the execution hereof, SHPI and BAS
hereby agree as follows:

I.       DEFINITIONS. The following terms are defined for purposes of this
         Agreement.

         1.1. "Effective Date" shall mean the date and year first written above.
         1.2. "Affiliate" shall mean any person or corporation or other business
entity controlled by, controlling, or under common control with a party to this
Agreement.
         1.3. "Act" shall mean the United States Food, Drug and Cosmetic Act of
1938, as amended and all regulations promulgated pursuant thereto, and any state
and local laws and regulations thereunder promulgated and all similar laws and
regulations of any other country or relevant jurisdiction related to the
development, manufacture, sale or distribution of Products.
         1.4. "Products" shall mean the power injectable safety winged infusion
sets developed by SHPI pursuant to this Agreement as described in Exhibit A
attached hereto and any improvements thereto.
         1.5. "Specifications" shall mean the raw material, manufacturing,
quality assurance, packaging and finished product specifications and protocols
relating to the Products as set forth in Exhibit A, as the same may be modified
and/or supplemented pursuant to the provisions hereof.

<PAGE>

         1.6. "Field" shall mean the accessing of implantable ports.
         1.7. "Territory" shall mean hospitals and alternate care sites
throughout the world. "Territory" includes homecare services, nursing homes,
oncology centers, infusion centers, same day surgery centers, physician offices
and clinics, non-hospital pharmacies and pain clinics.
         1.8. "Confidential Information" shall mean any information of a
confidential and/or proprietary nature as to which BAS or an Affiliate of BAS or
SHPI or an Affiliate of SHPI, as the disclosing party, prior to or during the
term of this Agreement, develops or acquires any interest, including but not
limited to, all discoveries, inventions, improvements, and ideas relating to any
process, formula, machine, device, manufacture, composition of matter, plan or
design, whether patentable or not, or relating to the conduct of business by the
disclosing party (including the existence and subject matter of this Agreement)
which, prior to or during the term of this Agreement, was or is disclosed to the
other party, as the receiving party, exclusive of data or information: (i)
which, at the time of disclosure hereunder, was in the public domain or which,
subsequent to disclosure hereunder, becomes part of the public domain by any
means other than the breach by the receiving party of its obligations hereunder;
(ii) which was known to the receiving party, at the time of disclosure
hereunder, as evidenced by the receiving party's business records maintained in
the ordinary course of business; (iii) which is, at any time, disclosed to the
receiving party by any person or entity not a party hereto whom the receiving
party believes, after reasonable inquiry, has the right to disclose the same;
(iv) which is developed by an employee of the receiving party who is shown, by
competent proof and by clear and convincing evidence, not to have been privy to
information disclosed by the disclosing party; or (v) which is disclosed
verbally, except where the disclosing party reduces the verbal disclosure to
writing, marks the same as confidential and proprietary and furnishes the
receiving party with the reduction to writing within thirty (30) days of the
verbal disclosure.
         1.9. "Contract Year" shall mean the twelve (12) month period commencing
on the date of the first Commercial Sale and each successive twelve (12) month
period thereafter.
         1.10. "Commercial Sale" shall mean the first arms length sale of a
Product, other than for clinical use required to obtain Regulatory Approval, in
any country of the world by BAS or a BAS Affiliate to a non-affiliated third
party
         1.11. "Development Program" shall mean those research, development and
other services or activities relating to the development, testing,
manufacturing, production and evaluation of the Product(s), all as contained in
and as more fully described in Schedule 1.11.

                                       2
<PAGE>

         1.12. "Regulatory Approval" shall mean the notification to or
concurrence, acknowledgment, or approval of any governmental or
quasi-governmental agency or regulatory body, which notification, concurrence,
acknowledgment or approval is necessary for or useful to the manufacturing,
processing, marketing or sale of Products anywhere in the world, and which is
made in the name of SHPI or has been given/granted on behalf of SHPI.
         1.13 "Trademarks" shall mean U.S. Trademark Application No. 78/630,704
for PowerLoc(TM), and all international and common law trademark rights to
PowerLoc.
         1.14 "510(k)" shall mean a pre-market approval notification, as defined
in Section 510(k) of the Act.
         1.15 "CE mark" shall mean the Communite de European mark commonly known
as the CE Mark.
         1.16 "First Distribution Agreement" shall mean that Distribution
Agreement between SHPI and BAS dated September 17, 2001.
         1.17 "Development Program Funding" shall mean the amount of ** to be
paid by BAS to SHPI to fund the Development Program.

II.      REPRESENTATIONS AND WARRANTIES

         2.1. SHPI Representations and Warranties. SHPI hereby represents and
warrants to BAS:
                  (a) that SHPI is not currently a party to any agreement, oral
         or written, which would, in any manner, be inconsistent with the rights
         herein granted to BAS, and shall not enter into any such agreement or
         understanding, oral or written, during the term of this Agreement, nor,
         during the term of this Agreement, directly or indirectly, will engage
         in any activity which would, in any manner, be inconsistent with the
         rights herein granted to BAS;
                  (b) that SHPI is a corporation organized, validly existing and
         in good standing under the laws of Utah, has all requisite corporate
         power and authority to own and operate its property and to carry on its
         business as now being conducted and is duly qualified and in good
         standing to do business in any of those jurisdictions where it is
         required to be qualified;
                  (c) that the execution and delivery of this Agreement by SHPI
         has been duly and validly authorized by all necessary corporate action
         on the part of SHPI and that (assuming valid execution by BAS where
         applicable and subject to federal bankruptcy law) this Agreement is a
         valid and binding obligation of SHPI enforceable against it; and
                  (d) all Products will have 510(k) approval. SHPI will submit a
         CE mark application for the Products upon its completion of the
         manufacturing startup phase in accordance with its SOP04-001.
---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

                                       3
<PAGE>

         2.2. BAS Representations and Warranties. BAS hereby represents and
warrants to SHPI:
                  (a) that BAS is a corporation organized, validly existing and
         in good standing under the laws of Utah, has all requisite corporate
         power and authority to own and operate its property and to carry on its
         business as now being conducted and is duly qualified and in good
         standing to do business in any of those jurisdictions where it is
         required to be qualified as a result of ownership of property or
         residence of any of its employees or agents, and
                  (b) that the execution and delivery of this Agreement by BAS
         has been duly and validly authorized by all necessary corporate action
         on the part of BAS and that (assuming valid execution by SHPI and
         subject to federal bankruptcy law) this Agreement is a valid and
         binding obligation of BAS enforceable against it, and
                  (c) that BAS is not currently a party to any agreement or
         understanding, oral or written, which would, in any manner, be
         inconsistent with its obligations described herein and shall not enter
         into any such agreement or understanding, oral or written, during the
         term of this Agreement, nor, during the term of this Agreement,
         directly or indirectly, engage in any activity which would, in any
         manner, be inconsistent with its obligations described herein, and
                  (d) that it is registered with the Food and Drug
         Administration and authorized to sell the Products.

III.     DEVELOPMENT PROGRAM.

         3.1 Funding. In consideration for the distribution rights granted in
this Agreement, BAS hereby covenants to fund the Development Program to the
extent of the Development Program Funding. The parties specifically acknowledge
that SHPI shall remain solely liable for all costs and expenses related to the
Development Program that exceed the Development Program Funding, unless the
parties make changes to the Development Program or the Specifications. Within
ten (10) days of the close of each month in which SHPI incurs any out-of-pocket
expenses in conjunction with the Development Program, SHPI will furnish BAS with
a written statement documenting such expenses incurred during that month, in a
form, and accompanied by such documentation or receipts, as may be reasonably
satisfactory to BAS. BAS shall pay from the Development Program Funding the
amount of the expenses covered by each such statement within thirty (30) days of
its receipt thereof. Any portion of the Development Program Funding that remains
unpaid at the time of SHPI's delivery of the first Product to BAS after
Regulatory Approval by the United States Food and Drug Administration shall
become immediately payable. If a party proposes to make a change to the
Development Program or the Specifications, the parties shall follow the
procedure set forth in Section 6.4 (relating to modifications in
Specifications). To the extent that the proposed modification results in a delay
or greater expense in concluding the Development Program, the parties shall
jointly examine and mutually agree upon the consequences and the proportion to
which each party will be responsible for the additional time and expenses.

                                       4
<PAGE>

         3.2 Diligence. The parties agree that the milestones shall be as set
forth in the Development Program and that both parties shall use all
commercially reasonable efforts to achieve such milestones in the Development
Program unless otherwise agreed in writing by the parties. If the Development
Program is not completed by January 1, 2006, BAS may, upon written notice to
SHPI, terminate this Agreement without any liability to SHPI, unless such delay
is attributable to BAS.
         3.3 Intellectual Property. As between the parties, each party shall
retain sole ownership of all ideas, inventions, processes, compounds and
methods, whether patentable or unpatentable, which have or potentially have,
utility in the Development Program and which prior to the date of this Agreement
or during the term of this Agreement, are conceived, developed, reduced to
practice or acquired by it alone or jointly with a third party. All ideas,
inventions, processes, compounds and methods, whether patentable or
unpatentable, which during the term of this Agreement, are jointly conceived,
developed, reduced to practice or acquired by the parties shall be jointly owned
by the parties.

IV.      DISTRIBUTION OF PRODUCTS

         4.1. Appointment of BAS as Distributor. Subject to the terms and
conditions hereof, SHPI hereby appoints BAS, and BAS hereby agrees to act, as
the exclusive distributor of Products in the Field throughout the Territory, for
the term of this Agreement.
         4.2. BAS's Responsibilities. BAS will use reasonable efforts to promote
sales and use of the Products in the Territory. SHPI hereby expressly
acknowledges and agrees that the grants set forth in Section 4.1 shall be deemed
to include a grant to BAS of the right to sell through any Affiliate of BAS and
through distributors of BAS or any Affiliate of BAS. Upon written request by
SHPI, BAS shall provide SHPI with a list of all BAS Affiliates and provide an
updated list on an annual basis.
         4.3. Device Complaints. BAS shall maintain a system of product
complaint recording and reporting wherein it will record the details of product
complaints it receives. BAS agrees to send copies of the complaint reports
relating to substantial design, technical or quality issues to SHPI. SHPI shall
be responsible for supporting BAS's investigation of such complaint reports.
SHPI shall, within thirty (30) days after SHPI receives the initial complaint
reports from BAS, forward the findings of the investigation to BAS.
         4.4. Recall. If BAS or SHPI are required by any competent governmental
authority to conduct a recall of any of the Products or either party determines
in its reasonable business judgment that a voluntary recall of any Product is
required (and in the instance of a voluntary recall with the consent of the
other party hereto, which neither SHPI nor BAS will unreasonably withhold), then
SHPI shall bear all expenses of SHPI and all reasonable expenses of BAS related
to the recall as it pertains to the Products. The parties will cooperate in good
faith on all aspects of a recall, but BAS shall have primary responsibility for
communications with end-users. Reporting to regulatory authorities in order to
satisfy legal requirements with respect to recalls shall be initiated by SHPI.
Both parties shall comply with applicable law in initiating and administering
recalls and render the regulatory authorities full cooperation during all recall
investigations and follow-up actions.

                                       5
<PAGE>

         4.5 Traceability Reporting in Canada. SHPI shall have the right, up to
four times per year, to request and receive from BAS a traceability report of
Products shipped into Canada, such report to include a current status of
specified lot(s), an identification of customers receiving shipments and a
report of any Product remaining in BAS's inventory. Health Canada Medical Device
Regulations also require that BAS's maintain records sufficient to facilitate
withdrawal of the Products from the market should a recall be necessary. Such
records must be kept for the longer of (i) the projected useful life of the
Product or (b) two years from shipment of the Product by BAS to its customer.

V.       TERMS OF PURCHASE AND SALE

         5.1. Purchase Orders. All sales and purchases of Products shall be
initiated pursuant to BAS's purchase order for the same placed with SHPI. All
such sales and purchases shall be governed by the terms and provisions of this
Agreement and any such purchase order, provided that in the event there is a
conflict between the terms of this Agreement and any of the terms of such
purchase order, the terms of this Agreement shall prevail. Purchase orders shall
be issued by BAS at the beginning of the preceding quarter and shall set forth
the quantity of each item ordered and the required delivery dates. Each purchase
order issued by BAS hereunder shall be accompanied by a non-binding forecast of
BAS's anticipated orders during each of the succeeding three (3) quarters.
Insomuch as these requirements are met, delivery of Products shall be made
within forty-five (45) days from receipt of purchase order, or on a later date
specified by BAS. All purchase orders issued by BAS hereunder shall be firm and
non-cancelable.
         5.2. Selling Price. SHPI and BAS hereby agree that: (i) the selling
prices by SHPI to BAS shall be for each unit Product in a fully-finished form in
accordance with applicable Specifications; and (ii) the initial selling prices
by SHPI to BAS of each unit of Product shall be as set forth on ExhibitB, which
is attached hereto and incorporated herein. After the first Contract Year, and
thereafter, on or about the completion of each succeeding Contract Year, the
parties shall jointly discuss any necessary revisions to the selling prices of
the Products. Any adjustments to the selling prices shall not exceed the
documented increases or decreases in manufacturing and/or raw materials costs of
the Products since SHPI's initial delivery of the Products to BAS or the last
such increase, as the case may be. All documentation of increased or decreased
costs provided by SHPI to BAS pursuant to this Section 5.2 shall be accompanied
by a certification of the chief financial officer of SHPI as to its accuracy.
Upon reasonable prior notice, BAS shall have the right during normal business
hours to audit SHPI's records to verify any such increase or decrease.
         5.3. Delivery. SHPI shall use commercially reasonable efforts to
manufacture and deliver Products to BAS, but in no case will SHPI be obligated
to deliver more than 30% over the forecasted volumes for a quarter, as such
forecast is determined in accordance with Section 5.1. BAS shall provide up to
six (6) months notice for changes to the forecast as described in Section 5.1 if
the increase in volume is more than 30% of the amount forecasted.

                                       6
<PAGE>

         5.4. Payment and Shipment. Shipment shall be in accordance with BAS's
instructions. SHPI shall invoice BAS for Products at the time of shipment. All
payments shall be due net thirty (30) days after shipment. All shipments of
sterile, single packaged Products shall be F.O.B. destination to BAS's facility
in Salt Lake City, Utah. All shipments of bulk, non-sterile Products shall be
F.O.B. destination to a BAS Affiliate facility in Renosa, Mexico. SHPI will
provide freight prepaid by common carrier. All other locations and means of
delivery will be specified at the time of purchase order and all associated
shipping costs will be paid by BAS.
         5.5. Minimum Purchase Requirements. BAS agrees to place purchase orders
with SHPI under this Agreement and the First Distribution Agreement in the
following cumulative quantities (hereinafter referred to as the "Minimum
Purchase Requirement"): ** units in the first Contract Year and ** units in each
Contract Year thereafter. **
         5.6 Competitive Products. The parties agree that nothing in this
Agreement shall restrict BAS's right to manufacture, market, sell and/or license
products or technologies competitive with Products. Both during and after the
term of this Agreement, SHPI shall not manufacture for, or sell or supply to,
any party other than BAS: (i) any power injectable safety winged infusion set
that utilizes any technology or information solely owned by Bard and provided by
Bard to SHPI in connection with the development of any Product; or (iii) any
component of a Product of the color purple, including but not limited to those
shades identified in the Pantone chart as 2587C and 2607C, unless government or
industry standards require the use of the color purple on such component. For
purposes of the prior sentence, components of a Product shall include, without
limitation, the needle hub, needle base, needle wings, tubing, tubing
connectors, and end caps but shall not include packaging or labeling.

VI.      MANUFACTURE OF PRODUCTS

         6.1. Representations and Warranties. SHPI hereby represents and
warrants to BAS:
                  (a) that each of the Products sold to BAS hereunder shall be
         manufactured in accordance with the requirements of the Quality Systems
         Regulations set forth in 21CFR, Parts 808, 812 and 820; and
                  (b) that each of the Products sold to BAS hereunder shall be
         new, free from defects in material and workmanship as defined by the
         Specifications, and comply in all respects with the applicable
         Specifications therefore; and
                  (c) that each of the Products sold to BAS hereunder will not,
         at the time of delivery to BAS, be adulterated or misbranded within the
         meaning of the Act or within the meaning of any jurisdiction in which
         the definitions of misbranding and adulterating are substantially the
         same as in the Act, nor, following FDA approval of Products, will any
         Product at the time of delivery to BAS be an article which may not,
         under the Act, be introduced into interstate commerce, and
---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

                                       7
<PAGE>

                  (d) that SHPI holds good and marketable title to all Products,
         and
                  (e) that all Products shall, at the time of delivery to BAS,
         have an expiration date of not less than 24 months from the date of
         manufacture. Products will be shipped to BAS having a remaining
         shelf-life of at least 12 months.
         6.2. Warranty Limitations. There are no other express or implied
warranties, including any warranty of merchantability or fitness for a
particular purpose. In the event of any breach of the warranties set forth in
Section 6.1 hereof, SHPI shall, at SHPI's sole cost and expense, at BAS's
option, repair or replace the Products which are non-conforming or defective, as
defined by the Specifications, within thirty (30) days of the return of such
item(s) to SHPI or shall credit BAS's account for the purchase price paid for
such item(s) by BAS upon the return thereof by BAS. All shipping costs incurred
incident to any such breach shall be borne by SHPI.
         6.3. Labeling. Product labeling shall have bar coding on the primary
and secondary packaging in compliance with the Health Industry Bar Coding
standards. No changes may be made to any Product labeling or packaging without
the prior written consent of BAS.
         6.4 Changes to Specifications. In the event that the Specifications are
proposed to be modified, the party seeking to make such modification shall
notify the other party as far in advance as is practicable prior to the proposed
effectiveness of such modification and the parties shall jointly agree on
whether and when to implement such modification. To the extent that such
modification results in an increase or decrease in the cost of manufacturing
and/or packaging the Products, the parties shall jointly examine and mutually
agree upon the consequences thereof and shall make appropriate adjustments to
the then current price in effect pursuant to Section 5.2. SHPI shall promptly
notify BAS of the date of implementation of any such modification.

VII.     TERM AND TERMINATION

         7.1. Term. This Agreement shall commence as of the date first above
written and shall remain in full force and effect through the end of the fifth
Contract Year. Thereafter, this Agreement shall be automatically renewed for
successive one-year terms unless terminated by BAS or SHPI by providing ninety
(90) days written notice to the other party at least ninety (90) days prior to
the expiration of the initial or any renewal term.
         7.2. Breach. Except as otherwise provided in this Agreement, in the
event of a material breach or default by either of the parties hereto of any
term or provision of this Agreement on their respective parts to be observed or
performed, the party who is not in breach or default shall have the right to
give the other party notice thereof, whereupon the party receiving such notice
shall have thirty (30) days to cure or cause the cure of such breach or default,
or if the same cannot reasonably be cured within such thirty (30) days, the
party receiving such notice shall, within said period, commence or have caused
the commencement of such cure and thereafter continue to diligently prosecute or
cause the prosecution of cure of the same. If such breach or default is so
cured, this Agreement shall remain in full force and effect. If such breach or

                                       8
<PAGE>

default is not so cured, this Agreement shall immediately terminate upon notice
of termination given to the party which failed to so cure such breach or
default. A material breach or default of this Agreement shall include, but is
not limited to, the following occurrences:
                  (i) after the placement by BAS of a purchase order, SHPI
         delivers Product volumes in an amount that is less than 80% of the
         forecast minimum volumes (as required in Section 4.1 herein) for three
         (3) consecutive months or three (3) times within any six (6) month
         period; or
                  (ii) more than 20% of the Products delivered by SHPI in two
         (2) consecutive months or in three (3) Products deliveries in any six
         (6) month period, fail to conform to the Specifications.
         7.3. By BAS. After the Second Contract Year BAS shall have the right to
terminate this Agreement at any time upon ninety (90) days prior written notice
to SHPI so long as BAS is not in breach of its obligations hereunder.
         7.4 By SHPI. After the Second Contract Year SHPI shall have the right
to terminate this Agreement at any time upon ninety (90) days prior written
notice to BAS so long as SHPI is not in breach of its obligations hereunder.
Notwithstanding, should BAS begin adding the Product to BAS port placement kits,
SHPI shall not have the right to terminate this Agreement without cause during
the Third and Fourth Contract Year so long as the Minimum Purchase Requirement
in Section 5.5 is met.
         7.5. Effect of Termination or Expiration. Expiration or prior
termination of this Agreement, for any reason, will not release either party
from any liability which at said time it has already incurred to the other
party, nor affect in any way the survival of any rights, duties or obligations
of either party which are expressly stated elsewhere in this Agreement to
survive said expiration or prior termination. Nothing in the immediately
preceding sentence will affect, be construed or operate as a waiver of the right
of the party aggrieved by any breach of this Agreement to be compensated for any
injury or damage resulting therefrom which is incurred before or after such
expiration or termination.

VIII.    REGULATORY MATTERS

         8.1. United States and European Union. SHPI shall obtain and comply
with all licenses, consents, permits and applicable laws and regulations,
including the Act, which may from time to time be required by appropriate
governmental authorities with respect to its manufacturing and packaging
processes at its facility and otherwise to permit the performance of its
obligations hereunder as well as the sale of the Products in the United States
and the European Union, including but not limited to the filing of a 510(k)
application with the United States Food and Drug Administration and the filing
of a CE Mark application with the European Union. SHPI agrees to provide BAS
with copies of all papers, concurrence and office actions pertaining to
regulatory communications with the United States Food and Drug Administration.
SHPI shall promptly transfer ownership of the aforementioned 510(k) application
to BAS at no cost. BAS shall not have the right to further transfer the 510(k)
other than to a BAS Affiliate. BAS shall register as the specification developer
and shall list the Products with the FDA.
         8.2. Other. SHPI shall provide BAS with whatever reasonable assistance
BAS may request, including providing its technical files and data, in

                                       9
<PAGE>

conjunction with BAS's initiating the registration or approval process for the
Products outside of the United States and the European Union. BAS agrees to
cover the reasonable costs associated with any unanticipated and extraordinary
data requests by governmental authorities. SHPI agrees to support all required
facility audits by regulatory bodies from those non FDA geographies where BAS or
SHPI has initiated the registration or approval process.

IX.      INTELLECTUAL PROPERTY MATTERS

         9.1 Infringement. In the event suit is filed against BAS or any
Affiliate of BAS by a third party alleging that the manufacture, use or sale of
any Product alone and not based upon its combination with any other article,
infringes the patent rights of such third party, BAS shall promptly notify SHPI
and shall include in its notice all facts in BAS's possession relating to the
same. In said event, SHPI hereby agrees to indemnify, save and hold BAS harmless
from and against all reasonable costs, liabilities and expenses (including
reasonable attorneys' fees) incident to any such suit. SHPI shall have the final
decision on all matters relating to such infringement litigation and any
settlement discussions. BAS will use reasonable efforts to cooperate with SHPI
in any such suit and shall have the right to consult with SHPI. It is expressly
agreed that SHPI shall have the duty to defend any action referred to in this
Section 9.1 utilizing counsel reasonably acceptable to the party charged and
such party shall have the right, at its own expense, to participate in any such
action utilizing counsel selected by it.
         9.2 Trademarks. In connection with SHPI's performance of this
Agreement, BAS hereby grants SHPI the right to reproduce and print on the
Products and/or Product packaging such trademarks, trade dress, brand names
and/or trade names of BAS, including the Trademarks, that BAS may designate in
writing from time to time, strictly in accordance with trademark usage and
packaging guidelines set forth in the Specifications or otherwise provided by
BAS. Samples of all such uses of BAS's trademarks, trade dress, brand names
and/or trade names on the Products or Product packaging shall be submitted to
BAS for its written approval prior to production. The permission granted to SHPI
herein is restricted to usage of such trademarks, trade dress, brand names
and/or trade names on or in connection with the Products supplied under this
Agreement, and such permission extends only for the term of this Agreement or
such shorter period as may be designated or required by BAS.
         Nothing set forth in this Agreement shall be construed to grant to SHPI
any title, right or interest in or to any trademark, trade dress, trade name,
brand name, copyright, patent or other proprietary technology owned by or
licensed to BAS or any of its Affiliates. SHPI's use of such trademarks, trade
dress, trade names, brand names, copyrights, patents or other proprietary
technology shall be limited exclusively to its performance of this Agreement.
Any other use of said trademarks, trade dress, trade names, brand names,
copyrights, patents or other proprietary technology (unless otherwise specified
herein) shall constitute an infringement thereof and/or violation of BAS's
rights.
         BAS acknowledges SHPI's trademarks, trade dress, trade names, brand
names, and/or copyrights incorporating "LOC" and that Section 9.2 in no way
limits or restricts SHPI's use of "LOC" with any current or future SHPI
trademarks, trade dress, trade names, brand names, and/or copyrights other than
"PowerLoc".

                                       10
<PAGE>

X.       INDEMNIFICATION/INSURANCE.

         10.1. Product Liability. SHPI and its Affiliates (collectively referred
to as "SHPI" for the purpose of this Section 10.1) hereby agree to indemnify,
save and hold BAS and its Affiliates harmless from and against all suits,
actions, claims, demands, judgments, liabilities and expenses which arise or
result from alleged injury (including death) incident to the use of any of the
Products and not based solely on the combination of such Products with other
products manufactured or sold by BAS. As a condition precedent to SHPI's
obligations under this Section 10.1, the party charged in such suit shall
promptly notify SHPI and shall not settle same without SHPI's prior written
approval. It is expressly agreed that SHPI shall have the duty to defend any
action referred to in this Section 10.1 utilizing counsel reasonably acceptable
to the party charged and such party shall have the right, at its own expense, to
participate in any such action utilizing counsel selected by it. Notwithstanding
the foregoing, it is understood and agreed that SHPI shall have no obligations
under this Section 10.1 for any suit, action, claim, demand, judgment, liability
or expense to the extent it is caused by the negligence, recklessness, willful
misconduct or breach of any of the terms of this Agreement by BAS, its
Affiliates or agents
         10.2. BAS Indemnity. BAS and its Affiliates (collectively referred to
as "BAS" for the purpose of this Section 10.2) hereby agree to indemnify, save
and hold SHPI and its Affiliates harmless from and against all suits, actions,
claims, demands, judgments, liabilities and expenses which arise or result from
BAS's activities in the sale and/or distribution of any Products. As a condition
precedent to BAS's obligations under this Section 10.2, the party charged in
such suit shall promptly notify BAS and shall not settle same without BAS's
prior written approval. Notwithstanding the foregoing, it is understood and
agreed that BAS shall have no obligations under this Section 10.2 for any suit,
action, claim, demand, judgment, liability or expense to the extent it is caused
by the negligence, recklessness, willful misconduct or breach of any of the
terms of this Agreement by SHPI, its Affiliates or agents.
         10.3. Insurance. SHPI hereby covenants to obtain and maintain, during
the term of this Agreement, a comprehensive general liability insurance policy,
with products liability endorsement, for the Products which policy shall be a
minimum amount of two million dollars ($2,000,000) per occurrence. Said policy
shall either name BAS and its Affiliates as additional insureds or shall provide
coverage via a broad form vendor's endorsement. Additionally, said policy shall
provide for not less than thirty (30) days prior written notice to BAS in the
event of any change in coverage or policy cancellation. SHPI hereby covenants to
deliver to BAS a certificate evidencing such coverage within ten (10) days of
the Effective Date.

XI.      MISCELLANEOUS

         11.1. Confidential Information. Each party shall hold in confidence any
Confidential Information disclosed by the other or otherwise obtained by such
party as a result of activities contemplated by this Agreement, and each party
shall protect the confidentiality thereof with the same degree of care that it
exercises with respect to its own information of a like nature, but in no event
less than reasonable care. Access to Confidential Information must be restricted
to the receiving party's employees, who, in each case, need to have access to

                                       11
<PAGE>

carry out a permitted use and are bound in writing to maintain the
confidentiality of such Confidential Information. The Confidential Information
and all copies of part or all thereof, shall be and remain the exclusive
property of the disclosing party, and the receiving party shall acquire only
such rights as are expressly set forth under the terms and conditions of this
Agreement and only for so long as such rights are in effect.
         11.2. Survival. The following Articles or Sections shall continue in
effect notwithstanding any termination of this Agreement: Article III, 5.6,
Article VI, 7.4, Article VIII, Article IX, Article X, 11.1, 11.5, 11.7 and
Article XII, and no termination of this Agreement shall relieve any party of
liability for a breach or violation of this Agreement occurring before such
termination.
          11.3. No Agency. This Agreement shall not constitute BAS the agent or
legal representative of SHPI for any purpose whatsoever and BAS shall not hold
itself out as an agent of SHPI. This Agreement creates no relationship of joint
venturers, partners, associates, employment or principal and agent between the
parties, and both parties are acting as independent contractors. BAS is not
granted herein any right or authority to and shall not attempt to assume or
create any obligation or responsibility for or on behalf of SHPI. BAS shall not
have any authority to bind SHPI to any contract, whether of employment or
otherwise, and BAS shall bear all of its own expenses for its operations,
including, without limitation, the compensation of its employees and salespeople
and the maintenance of its offices, service and warehouse facilities. BAS shall
be solely responsible for its own employees and salespeople and for their acts
and the things done by them.
         11.4. Amendments. This Agreement may be amended, modified or
supplemented only by a written instrument executed by the parties hereto.
         11.5. Waivers. No waiver of any provision of this Agreement, or consent
to any departure from the terms hereof, shall be effective unless the same shall
be in writing and signed by the party waiving or consenting thereto. No failure
on the part of any party to exercise and no delay in exercising, any right or
remedy hereunder shall operate as a waiver thereof, nor shall any single or
partial exercise of any such right or remedy by such party preclude any other or
further exercise thereof or the exercise of any other right or remedy. The
waiver by any party hereto of a breach of any provision of this Agreement shall
not operate as a waiver of any subsequent breach. All rights and remedies
hereunder are cumulative and are in addition to and not exclusive of any other
rights and remedies provided by law.
         11.6. Performance. Each party hereto acknowledges that money damages
alone will not adequately compensate such party for breach of such party's
obligations under Section 10.1 and, therefore, agrees that in the event of the
breach or threatened breach of any such obligation, in addition to all other
remedies available to the other party, at law, in equity or otherwise, such
other party shall be entitled to injunctive relief compelling specific
performance of, or other compliance with, the terms of such Section.
         11.7. Notices. Any notice or communication given pursuant to this
Agreement by any party to any other party shall be in writing and shall be
sufficiently given if personally delivered, sent by facsimile or other means of
confirmed electronic transmission or sent by a recognized next-day courier

                                       12
<PAGE>

service or by mail, postage prepaid to the parties at the following addresses or
to such other address as either party may hereafter designate to the others by
like notice:
              (a) if to SHPI, to:

                                 Specialized Health Products International, Inc.
                                 585 West 500 South
                                 Bountiful, Utah 84010
                                 Attention: General Counsel
                                 Facsimile Number: (801) 298-1759

              (b) if to BAS, to:
                                 Bard Access Systems, Inc.
                                 5425 West Amelia Earhart Drive
                                 Salt Lake City, Utah 84116
                                 Attention: President
                                 FAX Number: 801-595-4907

                                 with a copy to:

                                 C.R. Bard, Inc. 730
                                 Central Avenue
                                 Murray Hill, New Jersey 07974
                                 (908) 277-8000
                                 FAX Number: (908) 277-8025
                                 ATTENTION: General Counsel

         11.8. Expenses. Each party hereto shall pay its own expenses in
connection with the transactions contemplated hereby, whether or not they are
completed.
         11.9. Publicity. Except as required by applicable law or regulations,
neither party shall use the name of the other party in any publicity or
advertising without the prior written approval of the other party. Neither party
shall disclose any terms or conditions of this Agreement without the prior
written consent of the other party, provided, however, that either party, an
Affiliate of either party, or the corporate parent of either party may make such
disclosure to the extent that it reasonably believes such disclosure is
advisable or necessary for it to comply with the Federal Securities Laws or
other applicable law.
         11.10. Entire Agreement. This Agreement constitutes the entire
agreement among the parties hereto with respect to the subject matter hereof and
supersedes all negotiations, representations, warranties, commitments, offers,
contracts and writings prior to the date hereof.
         11.11. Governing Law. This Agreement shall be governed by and construed
and enforced in accordance with, the substantive laws of Utah, without giving
effect to its conflicts of law rules.
         11.12. Severability. Any provision of this Agreement which is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without
invalidating the remaining provisions hereof or affecting the validity or
enforceability of such provision in any other jurisdiction. In the event that
any provision of this Agreement shall be determined to be unenforceable by
reason of its extension for too great a period of time or over too large a

                                       13
<PAGE>

geographic area or over too great a range of activities, it shall be interpreted
to extend only over the maximum period of time, geographic area or range of
activities as to which it may be enforceable.
         11.13. Schedules. All Schedules mentioned in this Agreement shall be
attached to this Agreement and shall form an integral part hereof. All
capitalized terms defined in this Agreement which are used in any Schedule
shall, unless the context otherwise requires, have the same meaning therein as
given herein.
         11.14. Counterparts. This Agreement may be executed in two (2) or more
counterparts, including facsimile counterparts, all of which shall be considered
one and the same agreement and shall become effective when two (2) or more
counterparts have been signed by each of the parties and delivered to the other
parties, it being understood that all parties need not sign the same
counterpart.
         11.15. Assignments; Successors and Assigns. Neither party shall
transfer or assign (by operation of law or otherwise) its rights or obligations
under this Agreement without the prior written consent of the other party.
Notwithstanding the foregoing, either party will assign this Agreement in
connection with a sale or transfer of substantially all of the assets of, or a
majority interest in the voting shares of, that party to, or the merger or
consolidation of that party with or into, any other person or company on the
condition that any successor to or assignee of that party is and shall be bound
by all the terms, conditions and allegations under this Agreement, and that this
Agreement is and shall be incorporated into such assignment.
         11.16. Force Majeure. Either party shall be excused from delay in
performing or from its failure to perform hereunder to the extent that such
delay or failure results from any cause or causes beyond such party's reasonable
control, including: delay by any supplier in providing materials, parts or
services; delay by any carrier; fire; flood; acts of God; acts of war or
terrorism; labor dispute; riot; compliance with any applicable governmental act,
regulation or request; and shortage of labor, materials or manufacturing
facilities.
         11.17. Captions. The Article and Section headings contained in this
Agreement have been inserted for convenience of reference only and are not and
shall not be deemed or construed as constituting a part of this Agreement.

XII.     ARBITRATION

         12.1. In the event of a dispute of whatever nature arising between the
parties, including but not limited to, those arising out of or relating to this
Agreement or the construction, interpretation, performance, breach, termination,
enforceability or validity of this Agreement, the parties shall exercise good
faith efforts to resolve such dispute within a reasonable period of time. Should
the parties fail to reach agreement after thirty (30) days of good faith
negotiations, the parties agree to submit said dispute to binding arbitration.
Said arbitration shall take place in Salt Lake City, Utah, in accordance with
the rules of the American Arbitration Association. The arbitration panel shall
consist of one arbitrator selected by the American Arbitration Association
         12.2. The arbitration proceedings conducted pursuant hereto shall be
confidential. Neither party shall disclose or permit the disclosure of any
information about the evidence adduced or the documents produced by the other

                                       14
<PAGE>

party in the arbitration proceedings or about the existence, contents or results
of the arbitration award without the prior written consent of such other party
except in the course of judicial, regulatory or arbitration proceeding or as may
be required by a governmental authority. Before making any disclosure permitted
by the preceding sentence, the party intending to make such disclosure shall
give the other party reasonable written notice of the intended disclosure and
afford the other party reasonable opportunity to protect its interests.
         12.3. The arbitrators shall set forth in writing their findings of fact
and conclusions of law and shall render their award based thereon. Said award
shall be a final and binding judgement enforceable by a court of competent
jurisdiction.
         12.4. The party for whom the outcome of the arbitrators' decision is
less favorable (as determined by the arbitrators) shall be responsible for
reimbursing the other party for all fees and expenses of such party that are
directly related to the arbitration proceeding (including reasonable attorneys'
fees).

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
day and year first above written.

                                 SPECIALIZED HEALTH PRODUCTS INTERNATIONAL, INC.

                                 By: /s/ Jeffrey M. Soinski
                                     ----------------------------------------
                                 Name:    Jeffrey M. Soinski
                                 Title:   President & CEO

                                 BARD ACCESS SYSTEMS, INC.

                                 By: /s/ Jim Beasley
                                     ----------------------------------------
                                 Name: Jim Beasley
                                 Title: President

                                       15
<PAGE>

                                    EXHIBIT A

**

                                    EXHIBIT B

**

                                  SCHEDULE 1.11
**

---------------
The "**" marks the location of information that has been omitted and filed
separately with the Securities and Exchange Commission pursuant to a request for
confidential treatment.

                                       16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]